A randomized, prospective, active-controlled study comparing intramuscular long-acting paliperidone palmitate versus oral antipsychotics in patients with schizophrenia at risk of violent behavior

被引:1
|
作者
Wang, Gang [1 ]
Huang, Huiteng [1 ]
Wang, Yijun [1 ]
Yang, Yongde [1 ]
Li, Chang [1 ]
Luo, Sen [1 ]
Li, Yi [1 ,2 ]
机构
[1] Wuhan Mental Hlth Ctr, Wuhan, Peoples R China
[2] Wuhan Mental Hlth Ctr, 89 Gongnongbing Rd, Wuhan, Hubei, Peoples R China
关键词
Schizophrenia; Violence; Aggression; Paliperidone palmitate; Community-based; INJECTABLE ANTIPSYCHOTICS; MEDICATION ADHERENCE; FAMILY CAREGIVERS; SOCIAL COGNITION; BURDEN; PREVALENCE; CHINA;
D O I
10.1016/j.pnpbp.2023.110897
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: Paliperidone palmitate (PP) is an effective long-acting antipsychotic injection, but its impact on the behavior of schizophrenia patients with dangerous tendencies requires further investigation. This study aims to explore the effects of long-term antipsychotic treatment on this population in the community.Methods: This 49-week, randomized controlled trial was conducted across 21 communities in Wuhan and enrolled 134 schizophrenia patients at risk for violent behavior. With a fixed block size of 10, participants were randomly assigned to receive either intramuscular PP 1-month formulation (PP1M) or oral antipsychotic medication (OAP) at a 1:1 ratio. Changes in patients' risk for violent/aggressive behavior, family burden, social, and cognitive functioning were measured using VRAPP, MOAS, PANSS, FBS, PSP, and RBANS scales from baseline to endpoint. Longitudinal data from multiple repeated measures were analyzed using linear mixed-effects models.Results: The study protocol was completed by 77.6% of the patients overall. Significant improvements were observed in the risk assessment scores, MOAS total score, PANSS total score, PSP total score, and FBS total score of patients in the PP1M group from baseline to the end of treatment (all P < 0.05). Importantly, compared to patients in the OAP group, the improvements in these measures were also significantly greater in the PP1M group. Commonly observed AEs, such as hyperprolactinemia (70.3% vs. 62.65%) and muscle tension (45.3% vs. 57.8%), were considered to be the PP-related AEs. Nonetheless, the differences between the two groups did not reach statistical significance, and no new safety concerns emerged.Conclusions: Our study suggests that PP long-acting injection (LAI) is a safe and effective treatment option for community-dwelling schizophrenia patients with impulsive violence and risky behaviors.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Intramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychotics
    Hargarter, Ludger
    Cherubin, Pierre
    Bergmans, Paul
    Keim, Sofia
    Rancans, Elmars
    Bez, Yasin
    Parellad, Eduard
    Carpiniello, Bernardo
    Vidailhet, Pierre
    Schreiner, Andreas
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2015, 58 : 1 - 7
  • [2] COST OF LONG-ACTING RISPERIDONE INJECTION VERSUS LONG-ACTING PALIPERIDONE PALMITATE IN PATIENTS WITH SCHIZOPHRENIA IN RUSSIA
    Omelyanovsky, V
    Avxentyeva, M.
    Ivakhnenko, O.
    Khailov, P.
    Tsfasman, F. M.
    Krysanov, I
    Zorin, N.
    VALUE IN HEALTH, 2012, 15 (07) : A338 - A338
  • [3] Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics
    Alphs, Larry
    Bossie, Cynthia A.
    Sliwa, Jennifer Kern
    Fu, Dong-Jing
    Ma, Yi-Wen
    Hulihan, Joseph
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2013, 9 : 341 - 350
  • [4] COST-EFFECTIVENESS OF PALIPERIDONE PALMITATE LONG -ACTING INJECTABLE VERSUS ORAL ANTIPSYCHOTICS FOR THE TREATMENT OF PATIENTS WITH SCHIZOPHRENIA IN PERU
    Longaray, E.
    Guerrero, E.
    Aguirre, A.
    Hernandez, J.
    VALUE IN HEALTH, 2018, 21 : S185 - S185
  • [5] Earlier Use of Long-Acting Injectable Paliperidone Palmitate Versus Oral Antipsychotics in Patients With Schizophrenia: An Integrated Patient-Level Post Hoc Analysis
    Lopena, Oliver J.
    Alphs, Larry D.
    Sajatovic, Martha
    Turkoz, Ibrahim
    Sun, Liping
    Johnston, Karen L.
    Sliwa, Jennifer K.
    Najarian, Dean M.
    Starr, H. Lynn
    JOURNAL OF CLINICAL PSYCHIATRY, 2023, 84 (06)
  • [6] Prospective, randomized, multicenter clinical trial evaluating longitudinal changes in brain function and microstructure in first-episode schizophrenia patients treated with long-acting injectable paliperidone palmitate versus oral antipsychotics
    Wang, Chencai
    Tishler, Todd A.
    Oughourlian, Talia
    Nuechterlein, Keith H.
    de la Fuente-Sandoval, Camilo
    Ellingson, Benjamin M.
    SCHIZOPHRENIA RESEARCH, 2023, 255 : 222 - 232
  • [7] A randomized, double-blind study of paliperidone palmitate and risperidone long-acting therapy in schizophrenia
    Pandina, G.
    Lane, R.
    Gopal, S.
    Gassmann-Mayer, C.
    Hough, D.
    Remmerie, B.
    Simpson, G.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2010, 20 : S481 - S482
  • [8] Healthcare utilization and costs of veterans health administration patients with schizophrenia treated with paliperidone palmitate long-acting injection or oral atypical antipsychotics
    Baser, Onur
    Xie, Lin
    Pesa, Jacqueline
    Durkin, Mike
    JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (05) : 357 - 365
  • [9] Healthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitate
    Joshi, Kruti
    Pan, Xiaoyun
    Wang, Rosa
    Yang, Erru
    Benson, Carmela
    CURRENT MEDICAL RESEARCH AND OPINION, 2016, 32 (11) : 1873 - 1881
  • [10] A RANDOMIZED, ACTIVE-CONTROLLED RATER-BLINDED 2-YEAR STUDY OF PALIPERIDONE PALMITATE VERSUS INVESTIGATORS' CHOICE OF ORAL ANTIPSYCHOTIC MONOTHERAPY IN PATIENTS WITH SCHIZOPHRENIA (PROSIPAL)
    Schreiner, Andreas
    Aadamsoo, Kaire
    Altamura, Carlo
    Franco, Manuel
    Gorwood, Philip
    Neznanov, Nikolay G.
    Schronen, Juan
    Ucok, Alp
    Zink, Mathias
    Lahaye, Marjolein
    Hargarter, Ludger
    SCHIZOPHRENIA RESEARCH, 2014, 153 : S179 - S179